An effective, side effect-free topical emollient treatment for atopic dermatitis made from a sustainably procured seaweed extract

Informations projet

Fucoderm

N° de convention de subvention: 744737

DOI

10.3030/744737

Projet clôturé

Date de signature de la CE 6 Decembre 2016

Date de début 1 Decembre 2016

Date de fin 31 Mars 2017

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

GLYCOMAR LIMITED
United Kingdom

Periodic Reporting for period 1 - Fucoderm (An effective, side effect-free topical emollient treatment for atopic dermatitis made from a sustainably procured seaweed extract)

Période du rapport: 2016-12-01 au 2017-03-31

Résumé du contexte et des objectifs généraux du projet

GlycoMar intends to develop a novel topical cream for the management of mild to moderate eczema. The new product, ‘Fucobase’ will be suitable for long-term use and safe for both adults and children. The key objectives of the project are to finalise the Fucobase formulation, validate its safety and efficacy in humans, and commercialise the product as a CE certified medical device.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Throughout the duration of the Phase I project, GlycoMar reviewed the product development plan, secured partners for further product development, expanded their knowledge of the eczema market and established a commercialisation strategy. The Phase 1 feasibility assessment established that a development plan for the Fucobase product is technically and commercially viable, and that implementation of an industrialisation and commercialisation plan should be pursued. SME Instrument Phase 2 funding could provide the correct amount of funding and support to allow the stated activities to be implemented successfully.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The proposed Fucobase product will provide mild to moderate eczema sufferers, with an effective, natural and universal treatment. Unlike many existing products, it will be suitable for use in both adults and children, due to minimal side effects. Fucobase will therefore contribute to a sustainable and innovative healthcare system in Europe by reducing the large medical and social costs caused by this common disease.

Fucobase